

Federico Oppenheimer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2930293/publications.pdf>

Version: 2024-02-01

123
papers

3,787
citations

109321

35
h-index

144013

57
g-index

129
all docs

129
docs citations

129
times ranked

4703
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of Success in Conversion from Calcineurin Inhibitor to Sirolimus in Chronic Allograft Dysfunction. <i>American Journal of Transplantation</i> , 2004, 4, 1869-1875.	4.7	229
2	Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1979-1991.	6.1	193
3	COVID-19 in transplant recipients: The Spanish experience. <i>American Journal of Transplantation</i> , 2021, 21, 1825-1837.	4.7	156
4	Losartan decreases plasma levels of TGF- β 21 in transplant patients with chronic allograft nephropathy. <i>Kidney International</i> , 1999, 56, 714-719.	5.2	142
5	Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. <i>American Journal of Transplantation</i> , 2019, 19, 3018-3034.	4.7	97
6	Effects of Losartan and Amlodipine on Intrarenal Hemodynamics and TGF- β 21 Plasma Levels in a Crossover Trial in Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 822-827.	6.1	96
7	Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas. <i>Transplantation Reviews</i> , 2011, 25, 91-101.	2.9	95
8	Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 620-635.	6.1	94
9	Estimated One-Year Glomerular Filtration Rate is the Best Predictor of Long-term Graft Function Following Renal Transplant. <i>Transplantation</i> , 2006, 81, 202-206.	1.0	91
10	Effect of Cinacalcet on Hypercalcemia and Bone Mineral Density in Renal Transplanted Patients With Secondary Hyperparathyroidism. <i>Transplantation</i> , 2008, 86, 413-417.	1.0	87
11	Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, iv39-iv46.	0.7	85
12	Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 488-493.	0.7	82
13	New concepts and best practices for management of pre- and post-transplantation cancer. <i>Transplantation Reviews</i> , 2012, 26, 261-279.	2.9	82
14	The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2269-2276.	0.7	81
15	Feasibility of Transvaginal Natural Orifice Transluminal Endoscopic Surgery "Assisted Living Donor Nephrectomy: Is Kidney Vaginal Delivery the Approach of the Future?. <i>European Urology</i> , 2011, 59, 1019-1025.	1.9	81
16	Role of transforming growth factor- β 21 in the progression of chronic allograft nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 114-116.	0.7	78
17	Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: A multicentric cohort study. <i>American Journal of Transplantation</i> , 2020, 20, 3030-3041.	4.7	78
18	The Influence of Innate Immunity Gene Receptors Polymorphisms in Renal Transplant Infections. <i>Transplantation</i> , 2007, 83, 1493-1500.	1.0	77

#	ARTICLE	IF	CITATIONS
19	Efficacy of Eculizumab in the Treatment of Recurrent Atypical Hemolytic-Uremic Syndrome After Renal Transplantation. <i>Transplantation</i> , 2010, 89, 903-904.	1.0	75
20	The impact of donor age on the results of renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, iii11-iii15.	0.7	70
21	Antiphospholipase A2 Receptor Antibody Levels Predict the Risk of Posttransplantation Recurrence of Membranous Nephropathy. <i>Transplantation</i> , 2015, 99, 1709-1714.	1.0	69
22	Characterization of β_1 T cell subsets in organ transplantation. <i>Transplant International</i> , 2010, 23, 1045-1055.	1.6	68
23	Renal transplantation in HIV-infected patients: 2010 update. <i>Kidney International</i> , 2011, 79, 825-842.	5.2	65
24	mTOR inhibitor-associated proteinuria in kidney transplant recipients. <i>Transplantation Reviews</i> , 2012, 26, 27-29.	2.9	65
25	The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. <i>Transplantation Reviews</i> , 2014, 28, 84-91.	2.9	65
26	Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single center cohort of kidney recipients. <i>American Journal of Transplantation</i> , 2020, 20, 2958-2959.	4.7	65
27	<i>Toxoplasma gondii</i> primary infection in renal transplant recipients. Two case reports and literature review. <i>Transplant International</i> , 2011, 24, e6-e12.	1.6	62
28	Orthotopic Kidney Transplantation: An Alternative Surgical Technique in Selected Patients. <i>European Urology</i> , 2010, 58, 927-933.	1.9	49
29	Cysteamine (Cystagon(R)) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adults. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 475-480.	0.7	47
30	Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease. <i>Kidney International</i> , 2008, 74, S94-S99.	5.2	46
31	Follow-up after renal transplantation with organs from donors after cardiac death. <i>Transplant International</i> , 2006, 19, 715-719.	1.6	45
32	Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. <i>Kidney International</i> , 2014, 85, 1434-1443.	5.2	38
33	Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3784-3793.	0.7	37
34	Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation. <i>Clinical Transplantation</i> , 2013, 27, 338-347.	1.6	37
35	Weekly risedronate in kidney transplant patients with osteopenia. <i>Transplant International</i> , 2007, 20, 708-711.	1.6	35
36	Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover. <i>Journal of Bone and Mineral Metabolism</i> , 2004, 22, 254-259.	2.7	32

#	ARTICLE	IF	CITATIONS
37	Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2316-2321.	0.7	32
38	Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study. <i>Transplant International</i> , 2013, 26, 177-186.	1.6	32
39	Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection. <i>BMC Nephrology</i> , 2018, 19, 261.	1.8	31
40	Renoprotective Effects of Losartan in Renal Transplant Recipients. <i>Nephron Clinical Practice</i> , 2003, 95, c84-c90.	2.3	27
41	Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria. <i>Transplant International</i> , 2007, 21, 071115125226003-???	1.6	27
42	Sympathetic Dystrophy Associated With Sirolimus Therapy. <i>Transplantation</i> , 2008, 85, 290-292.	1.0	26
43	Kidneys From Donors With Incidental Renal Tumors. <i>Transplantation</i> , 2013, 95, 1129-1133.	1.0	25
44	Fluvastatin in the Prevention of Renal Transplant Vasculopathy: Results of a Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Transplantation</i> , 2008, 86, 82-87.	1.0	24
45	Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study. <i>BMJ Open</i> , 2021, 11, e052138.	1.9	24
46	Percutaneous renal artery embolisation of non-functioning renal allografts with clinical intolerance. <i>Transplant International</i> , 2002, 15, 149-155.	1.6	23
47	Tacrolimus Pharmacokinetics of Once- Versus Twice-Daily Formulations in De Novo Kidney Transplantation. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 143-147.	2.0	23
48	Renal Dysfunction in the Setting of HIV/AIDS. <i>Current HIV/AIDS Reports</i> , 2012, 9, 187-199.	3.1	22
49	Histopathological evaluation of pretransplant donor biopsies in expanded criteria donors with high kidney donor profile index: a retrospective observational cohort study. <i>Transplant International</i> , 2017, 30, 975-986.	1.6	22
50	Cystinosis in adult and adolescent patients: Recommendations for the comprehensive care of cystinosis. <i>Nefrologia</i> , 2015, 35, 304-321.	0.4	21
51	Impact of Mesenchymal Stromal Cells and Their Extracellular Vesicles in a Rat Model of Kidney Rejection. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 10.	3.7	21
52	Distinct Immunohistochemical Phenotype of Nonmelanoma Skin Cancers Between Renal Transplant and Immunocompetent Populations. <i>Transplantation</i> , 2010, 90, 986-992.	1.0	20
53	TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation. <i>Open Access Journal of Clinical Trials</i> , 2014, , 45.	1.5	19
54	Renal Transplantation in Systemic Lupus Erythematosus: Outcome and Prognostic Factors in 50 Cases from a Single Centre. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	19

#	ARTICLE	IF	CITATIONS
55	Renal transplantation in patients with hepatitis C virus antibody. A long national experience. <i>CKJ: Clinical Kidney Journal</i> , 2010, 3, ii41-ii46.	2.9	18
56	Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination in Kidney Transplant Recipients. <i>Transplantation</i> , 2022, 106, 1430-1439.	1.0	18
57	Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation. <i>Transplant International</i> , 2016, 29, 1317-1328.	1.6	16
58	Assessment of donor satisfaction as an essential part of living donor kidney transplantation: an eleven-year retrospective study. <i>Transplant International</i> , 2018, 31, 1332-1344.	1.6	16
59	Sequential Quadruple Immunosuppression Including Sirolimus in Extended Criteria and Nonheartbeating Donor Kidney Transplantation. <i>Transplantation</i> , 2007, 84, 429-432.	1.0	15
60	Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection. <i>Transplantation</i> , 2018, 102, 1075-1084.	1.0	15
61	Ulnar nerve compression—a case of giant uremic tumoral calcinosis. <i>Acta Orthopaedica</i> , 1997, 68, 302-304.	1.4	13
62	Sirolimus Monotherapy: Feasible Immunosuppression for Long-Term Follow-up of Kidney Transplantation? A Pilot Experience. <i>Transplantation</i> , 2005, 80, 1344-1348.	1.0	12
63	Primary brain lymphomas after kidney transplantation: an under-recognized problem?. <i>Journal of Nephrology</i> , 2014, 27, 95-102.	2.0	12
64	Recomendaciones para el uso de everolimus en trasplante renal de novo: falsas creencias, mitos y realidades. <i>Nefrología</i> , 2017, 37, 253-266.	0.4	12
65	Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. <i>Transplantation Reviews</i> , 2019, 33, 191-199.	2.9	12
66	Impact of Long-Term Therapy With FTY720 or Mycophenolate Mofetil on Cardiac Conduction and Rhythm in Stable Adult Renal Transplant Patients. <i>Transplantation</i> , 2007, 83, 645-648.	1.0	11
67	Role of HHV-8 and mTOR pathway in post-transplant Kaposi sarcoma staging. <i>Transplant International</i> , 2016, 29, 1008-1016.	1.6	11
68	Effect of immunosuppression in miRNAs from extracellular vesicles of colorectal cancer and their influence on the pre-metastatic niche. <i>Scientific Reports</i> , 2019, 9, 11177.	3.3	11
69	mTOR Inhibition. <i>Transplantation Direct</i> , 2016, 2, e65.	1.6	10
70	Health-Related Quality of Life of Patients Receiving Low-toxicity Immunosuppressive Regimens: A Substudy of the Symphony Study. <i>Transplantation</i> , 2009, 87, 1210-1213.	1.0	9
71	An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI. <i>Transplant International</i> , 2016, 29, 362-368.	1.6	9
72	Pancreas outcomes between living and deceased kidney donor in pancreas after kidney transplantation patients. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 2052-2059.	0.7	9

#	ARTICLE	IF	CITATIONS
73	The impact of functional delayed graft function in the modern era of kidney transplantation – A retrospective study. <i>Transplant International</i> , 2021, 34, 175-184.	1.6	9
74	A hybrid data envelopment analysis–artificial neural network prediction model for COVID-19 severity in transplant recipients. <i>Artificial Intelligence Review</i> , 2021, 54, 4653-4684.	15.7	9
75	Treatment With Sirolimus Is Associated With Less Weight Gain After Kidney Transplantation. <i>Transplantation</i> , 2013, 96, 480-486.	1.0	8
76	Identifying endpoints to predict the influence of immunosuppression on long-term kidney graft survival. <i>Clinical Transplantation</i> , 2015, 29, 644-653.	1.6	8
77	Psychosocial risk factors for impaired health-related quality of life in living kidney donors: results from the ELIPSY prospective study. <i>Scientific Reports</i> , 2020, 10, 21343.	3.3	8
78	Role of Oncogenic Pathways and KRAS/BRAF Mutations in the Behavior of Colon Adenocarcinoma in Renal Transplant Patients. <i>Transplantation</i> , 2012, 93, 509-517.	1.0	7
79	Long-term mycophenolate monotherapy in human leukocyte antigen (HLA)-identical living-donor kidney transplantation. <i>Transplantation Research</i> , 2014, 3, 4.	1.5	7
80	Polyclonal Versus Monoclonal Induction Therapy in a Calcineurin Inhibitor–Free Immunosuppressive Therapy in Renal Transplantation: A Comparison of Efficacy and Costs. <i>Transplantation Proceedings</i> , 2015, 47, 45-49.	0.6	7
81	Borderline rejection in ABO-incompatible kidney transplantation. <i>Clinical Transplantation</i> , 2016, 30, 872-879.	1.6	7
82	Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities. <i>Nefrologia</i> , 2017, 37, 253-266.	0.4	7
83	The development of a predictive model of graft function in uncontrolled donors after circulatory death: validity of a pulsatile renal preservation machine cut-off value for kidney acceptance. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 531-538.	0.7	7
84	Outcomes From Brain Death Donors With Previous Cardiac Arrest Accepted for Pancreas Transplantation. <i>Annals of Surgery</i> , 2021, 273, e230-e238.	4.2	7
85	Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients. <i>Clinical Transplantation</i> , 2007, 21, 441-448.	1.6	6
86	Desensitization in ABO-Incompatible Kidney Transplantation With Low ABO Iso-Agglutinin Titers. <i>Transplantation Proceedings</i> , 2015, 47, 2340-2343.	0.6	6
87	Perioperative prophylaxis with ertapenem reduced infections caused by extended-spectrum betalactamase-producing Enterobacteriaceae after kidney transplantation. <i>BMC Nephrology</i> , 2019, 20, 274.	1.8	6
88	Outcomes after 20 years of experience in minimally invasive living-donor nephrectomy. <i>World Journal of Urology</i> , 2022, 40, 807-813.	2.2	6
89	Are HIV-Infected Donors Suitable for Renal Transplantation?. <i>Transplantation</i> , 2011, 91, e22-e23.	1.0	5
90	Changes in bone mineral metabolism parameters, including FGF23, after discontinuing cinacalcet at kidney transplantation. <i>Endocrine</i> , 2015, 49, 267-273.	2.3	5

#	ARTICLE	IF	CITATIONS
91	Set point of calcium in severe secondary hyperparathyroidism is altered and does not change after successful kidney transplantation. <i>Endocrine</i> , 2015, 48, 709-711.	2.3	5
92	Successful use of nonantigen-specific immunoadsorption with antihuman IgG columns in kidney graft antibody-mediated rejection. <i>Journal of Clinical Apheresis</i> , 2020, 35, 188-199.	1.3	5
93	Taking care of kidney transplant recipients during the COVID-19 pandemic: Experience from a medicalized hotel. <i>Clinical Transplantation</i> , 2021, 35, e14132.	1.6	5
94	Modeling patients as decision making units: evaluating the efficiency of kidney transplantation through data envelopment analysis. <i>Health Care Management Science</i> , 2021, 24, 55-71.	2.6	5
95	SARS-CoV-2 Infection After Full Vaccination in Kidney Transplant Recipients. <i>Transplantation</i> , 2021, 105, e278-e279.	1.0	5
96	Treatment of humoral rejection in kidney transplantation. <i>Transplantation Reviews</i> , 2006, 20, 95-103.	2.9	4
97	Influence of Persistent Inflammation in Follow-Up Biopsies After Antibody-Mediated Rejection in Kidney Transplantation. <i>Frontiers in Medicine</i> , 2021, 8, 761919.	2.6	4
98	B Cell-Derived Extracellular Vesicles Reveal Residual B Cell Activity in Kidney Graft Recipients Undergoing Pre-Transplant Desensitization. <i>Frontiers in Medicine</i> , 2021, 8, 781239.	2.6	4
99	A case of esophageal adenocarcinoma on long-term rapamycin monotherapy. <i>Transplant International</i> , 2015, 28, 1240-1244.	1.6	3
100	Regional differences in the management and outcome of kidney transplantation in patients with human immunodeficiency virus infection: A 3-year retrospective cohort study. <i>Transplant Infectious Disease</i> , 2017, 19, e12724.	1.7	3
101	Impact of Discards for Living Donor Kidney Transplantation in a Transplant Program. <i>Transplantation Proceedings</i> , 2019, 51, 3222-3226.	0.6	3
102	Simultaneous Aortic Bifurcation Graft and Kidney Transplantation from the same Multi-Organ Donor: A New Therapeutic Tool in Complex Renal Transplantation. <i>Journal of Urology</i> , 1996, 156, 2000-2001.	0.4	2
103	Indium-111 labelled platelet scintigraphy can predict the immunological origin of fever in patients on dialysis carrying a non-functioning renal allograft. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 314-318.	6.4	2
104	KIDNEY OUTCOME IN THE CONTEXT OF COMBINED LIVER- KIDNEY TRANSPLANTATION. <i>Journal of Urology</i> , 2008, 179, 695-696.	0.4	2
105	Monoclonal gammopathy of undetermined significance: a contraindication for living kidney donation?. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 256-257.	2.9	2
106	Safety of hepatitis C virus (HCV)-treated donors for kidney transplantation excluding occult HCV infection through kidney biopsies. <i>Transplant International</i> , 2018, 31, 938-939.	1.6	2
107	Preemptive Use of Mammalian Target of Rapamycin Inhibitors in Living Donor Transplantation. <i>Transplantation Proceedings</i> , 2011, 43, 2568-2573.	0.6	1
108	Renal Function Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus with Reduced-Exposure Calcineurin Inhibitor versus Mycophenolate with Standard-Exposure Calcineurin Inhibitor. <i>Transplantation</i> , 2018, 102, S363.	1.0	1

#	ARTICLE	IF	CITATIONS
109	The Case Persistent fever in a hemodialysis patient. <i>Kidney International</i> , 2022, 101, 193-194.	5.2	1
110	MO957: Breakthrough Infections Following Mrna Sars-Cov-2 Vaccination in Kidney Transplant Recipients. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	1
111	KIDNEY TRANSPLANT FROM DONORS AFTER UNEXPECTED CARDIAC DEATH (DCD). <i>Journal of Urology</i> , 2008, 179, 662-663.	0.4	0
112	PULSATILE PERFUSION IMPROVES KIDNEY PRESERVATION AND PROVIDES INFORMATION ABOUT ORGAN VIABILITY IN ORGANS FROM EXPANDED CRITERIA DONORS. <i>Journal of Urology</i> , 2009, 181, 805-806.	0.4	0
113	Reply to Ramya Nagarajan, Shanmugasundaram Rajaian, Nitin S. Kekre's Letter to the Editor re: Mireia Musquera, Lluís L. Peri, Ricardo Alvarez-Vijande, et al. Orthotopic Kidney Transplantation: An Alternative Surgical Technique in Selected Patients. <i>Eur Urol</i> 2010;58:927-933. <i>European Urology</i> , 2011, 59, e28.	1.9	0
114	FP899DEGREE OF LIVER INVOLVEMENT IN STABLE KIDNEY TRANSPLANT PATIENTS WITH HEPATITIS C INFECTION: A SINGLE-CENTER EXPERIENCE. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii376-iii376.	0.7	0
115	Different Patterns of Risk Factors for Mortality according Recipient Age after Renal Transplantation. A Multicenter and Prospective Study at Ten Years in the Clinical Practice. <i>Transplantation</i> , 2018, 102, S191.	1.0	0
116	Pancreas Graft Outcomes in Living versus Deceased Kidney Donor in Pancreas after Kidney Transplant Recipients. <i>Transplantation</i> , 2018, 102, S449.	1.0	0
117	Outcomes from Brain Death Donors with Cardiac Arrest Accepted for Pancreas Transplantation. <i>Transplantation</i> , 2018, 102, S450.	1.0	0
118	P1699EFFECT OF UREMIA IN THE POSTOPERATIVE OF PREEMPTIVE LIVING-DONOR KIDNEY TRANSPLANT PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
119	1690: Orthotopic Renal Transplant: An Alternative Surgical Technique in Selected Cases. <i>Journal of Urology</i> , 2006, 175, 544-544.	0.4	0
120	Chronic renal patient across the continuum of the healthcare from family practitioner to nephrologists. <i>International Journal of Integrated Care</i> , 2016, 16, 228.	0.2	0
121	FC 107: Development and Validation of a Machine Learning-Based Virtual Biopsy System in Kidney Transplant Patients. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
122	FC002: Humoral and Cellular Immune Responses After a Three-Dose Course of Mrna-1273 Covid-19 Vaccine in Kidney Transplant Recipients: A Prospective Cohort Study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
123	FC 110: Survival Benefit of Preemptive Simultaneous Pancreas-Kidney Transplantation. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0